Climb Bio (CLYM) Long-Term Investments (2021 - 2026)

Climb Bio (CLYM) has 5 years of Long-Term Investments data on file, last reported at $36.7 million in Q1 2026.

• Quarterly Long-Term Investments fell 63.18% year-over-year to $36.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.7 million (down 63.18% YoY) and the FY2025 annual result came in at $59.6 million, down 3.31% from the prior year.
• Long-Term Investments retreated to $36.7 million in Q1 2026, from $59.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $102.7 million in Q2 2025 to a low of $7.0 million in Q3 2022.
• A 4-year average of $51.8 million and a median of $48.2 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments plunged 70.53% — and 2025, when it surged 261.86%.
• Tracing CLYM's Long-Term Investments over 4 years: stood at $7.0 million in 2022, then soared by 785.07% to $61.6 million in 2024, then retreated by 3.31% to $59.6 million in 2025, then plunged by 38.33% to $36.7 million in 2026.
• The last three Long-Term Investments figures came in at $36.7 million (Q1 2026), $59.6 million (Q4 2025), and $88.9 million (Q3 2025), per Business Quant data.